Literature DB >> 10198334

Effects of IBMX on norepinephrine-induced vasoconstriction in small mesenteric arteries.

M S Taylor1, H Gao, J D Gardner, J N Benoit.   

Abstract

The present study assesses the effects of the phosphodiesterase inhibitor IBMX on norepinephrine (NE)-induced constriction of small mesenteric arteries. Arteries ( approximately 150 micrometer) were dissected from rats and mounted on a wire myograph for isometric force measurement. NE concentration effect curves were generated after exposure to 500 microM IBMX for 60 min. IBMX significantly reduced NE-induced tension development. Studies were also conducted following sarcoplasmic reticulum (SR) depletion (ryanodine, 10 microM) or L-type Ca2+ channel blockade [(+)-BAY K 8644, 10 microM] in the presence and absence of IBMX. Both SR depletion and L-channel blockade reduced NE-induced tension generation, consistent with incomplete Ca2+ mobilization. IBMX significantly attenuated NE responses in ryanodine and (+)-BAY K 8644-treated vessels. Finally, treatment of NE-stimulated vessels with IBMX (500 microM) caused a reduction in vascular tension that was greater than the concomitant reduction in cytosolic Ca2+ concentration ([Ca2+]i), indicating that a portion of the IBMX-mediated relaxation is Ca2+-independent. These data suggest that IBMX attenuation of NE responsiveness not only involves a reduction in [Ca2+]i but also a significant decrease in Ca2+ sensitivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10198334     DOI: 10.1152/ajpgi.1999.276.4.G909

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  2 in total

1.  P2Y(1) and P2Y(2) receptors are coupled to the NO/cGMP pathway to vasodilate the rat arterial mesenteric bed.

Authors:  Sonja Buvinic; René Briones; J Pablo Huidobro-Toro
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

2.  Voltage-dependent inward currents in smooth muscle cells of skeletal muscle arterioles.

Authors:  Alexandra V Ulyanova; Roman E Shirokov
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.